Effect of the Combined Programme on Perioperative Anaemia(CPPA)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

We used the preoperative intervention of iron sucrose in combination with human erythropoietin and vitamin C as an innovative combination therapy. This combined treatment strategy aims to improve perioperative anaemia in patients by promoting erythropoiesis and improving iron metabolism. Compared with previous perioperative intravenous iron supplementation, this innovative combination therapy strategy takes into account multiple aspects of iron metabolism as well as the biological mechanisms of erythropoiesis, providing a more comprehensive intervention. Management of perioperative anaemia in previous studies has largely relied on single intravenous iron supplementation therapy, and although this approach has been effective in raising iron levels, its effectiveness may be limited in patients who have impaired iron utilisation or in situations where concurrent stimulation of erythropoiesis is required. The use of iron sucrose in combination with human erythropoietin and vitamin C, on the other hand, is based on an integrative therapeutic concept aimed at providing a more comprehensive response to perioperative anaemia by simultaneously promoting effective iron utilisation and erythropoiesis.

Eligibility criteria

Qualifiers

Age 18 years and above

Ferritin <300µg/L, transferrin saturation <25%, male 90<Hb<130g/L or female 90<Hb<120g/L

Elective major cardiac surgery (valve replacement, CABG coronary artery bypass surgery or a combination of both)

ASA: Grade 1-3

Disqualifiers

Allergy or contraindication to iron sucrose or recombinant human erythropoietin or ascorbic acid

Patients with a preoperative temperature >37.5 °C or on non-prophylactic antibiotics

Pregnancy or breastfeeding stage

weight ≤ 50 kg

Trial design

Treatments tested in this trial

  • Iron Sucrose, recombinant human erythropoietin, ascorbic acid
  • conventional treatment

Treatment groups

110 Participants
are divided into 2 treatment groups